Murat Alper

Murat Alper

Auto-generated profile, based on publicly available information

Murat Alper

Department of Pathology, Dıskapı Training and Research Hospital, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2010 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
ISIpek Suntar
Ipek Suntar
EAEsra Küpeli Akkol
Esra Küpeli Akkol
DYDemet Yılmazer
Demet Yılmazer
TBTurhan Baykal
Turhan Baykal
HKHasan Kırmızıbekmez
Hasan Kırmızıbekmez
EYErdem Yeşilada
Erdem Yeşilada

24 July 2006 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
ECE Cevher
E Cevher
ZOZ Orhan
Z Orhan
LML Mulazimoglu
L Mulazimoglu
DSD Sensoy
D Sensoy
MAM Alper
M Alper
YOY Ozsoy
Y Ozsoy

3 February 2003 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
FSFatma Silan
Fatma Silan
MYMieko Yoshioka
Mieko Yoshioka
KKKazuhiro Kobayashi
Kazuhiro Kobayashi
ESEnver Simsek
Enver Simsek
MTMurat Tunc
Murat Tunc
TTTatsushi Toda
Tatsushi Toda

1 December 2010 in Cancer Genetics and Cytogenetics
Verified
Journal Article
Closed access
BGBerrak Gumuskaya
Berrak Gumuskaya
MAMurat Alper
Murat Alper
SHSema Hucumenoglu
Sema Hucumenoglu
KAKadri Altundag
Kadri Altundag
AUAysegul Uner
Aysegul Uner
GGGulnur Guler
Gulnur Guler

1 March 2002 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
CBCan Baykal
Can Baykal
NBNesimi Bykbabani
Nesimi Bykbabani
AKAyse Kavak
Ayse Kavak
MAMurat Alper
Murat Alper

1 March 2008 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
NBNurdan Bedirli
Nurdan Bedirli
EOEbru Ofluoglu
Ebru Ofluoglu
MKMustafa Kerem
Mustafa Kerem
GUGulten Utebey
Gulten Utebey
MAMurat Alper
Murat Alper
HPHatice Pasaoglu
Hatice Pasaoglu
BACKGROUND: We investigated the effects of isoflurane and sevoflurane in a warm liver ischemia-reperfusion (IR) model on cytokines, hepatic tissue blood flow (HTBF), energy content, and liver structure. METHODS: Seventy-two Wistar rats were randomly assigned into 1 of 3 groups: Control group, no volatile anesthetics; sevoflurane group, 2% sevoflurane; isoflurane group, 1.5% isoflurane. Thirty minutes after the start of volatile anesthetics, rats were subjected to 45 min hepatic ischemia and 2 and 4 h of reperfusion. Rats were killed at the end of ischemia, 2 and 4 h of reperfusion. Aspartate aminotransferase and alanine aminotransferase, HTBF, malondialdehyde, tumor necrosis factor (TNF)-α, interleukin (IL)-1β, energy charge, and histologic examination were used to evaluate the extent of liver injury. RESULTS: Serum alanine aminotransferase and aspartate aminotransferase levels were similar in control and isoflurane groups while there was a significant decrease in the sevoflurane group in the postischemic period (P < 0.01). HTBF was remarkably better in the sevoflurane group than in the isoflurane group and worse in the control group. Tissue malondialdehyde levels were significantly low in the sevoflurane group compared with the isoflurane group at 2 h of reperfusion (P < 0.05) and reached its maximum value in the postischemic period in the control group. After ischemia, 2 and 4 h of reperfusion, tumor necrosis factor-α and interleukin-1β values were lowest in the sevoflurane group and highest in the control group but it was not statistically significant (P > 0.05). In the sevoflurane group, hepatic adenosine triphosphate and energy charge were significantly high at all measurement times. At the postischemic period, energy charge was lower compared with the sevoflurane and isoflurane groups. The degree of hepatocyte injury was small in the sevoflurane group. CONCLUSIONS: Clinically relevant concentrations of sevoflurane given before, during, and after hepatic ischemia protected the liver against IR injury, whereas the effects of isoflurane on hepatic IR injury were not notable.